Novavax’ COVID-19 vaccine candidate, called NVX-CoV2373, is being developed for the prevention of COVID-19 disease. NVX-CoV2373 is made from the genetic sequence of SARS‑CoV‑2, the virus that causes COVID-19 disease. It does not contain any live or inactivated virus, and cannot cause infection or COVID-19 disease.
The study vaccine was created using Novavax’ nanoparticle technology. The vaccine also contains the Company’s patented adjuvant called Matrix-MTM to boost the immune response and stimulate high levels of neutralizing antibodies.
The purpose of the Phase 3 study is to test the safety and efficacy of the vaccine. We want to understand how well the study vaccine works to prevent COVID-19 disease.
The study enrolled diverse populations, including those with other underlying health conditions, and in groups hardest hit by COVID-19 who are at high risk of developing severe disease. Visit ClinicalTrials.gov - NCT04611802 for additional details.
Content last reviewed on April 14, 2021